CN114729358A - 涉及miRNA-193a的新疗法 - Google Patents

涉及miRNA-193a的新疗法 Download PDF

Info

Publication number
CN114729358A
CN114729358A CN202080070230.9A CN202080070230A CN114729358A CN 114729358 A CN114729358 A CN 114729358A CN 202080070230 A CN202080070230 A CN 202080070230A CN 114729358 A CN114729358 A CN 114729358A
Authority
CN
China
Prior art keywords
mirna
cancer
pten
preferred
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080070230.9A
Other languages
English (en)
Chinese (zh)
Inventor
S·雅亚内贾德
B·J·泰尔福德
M·T·J·范德博世
M·F·阿莱姆德
M·M·德根斯
L·A·H·范平克斯特伦
R·Q·J·沙朴维尔德
M·简尼考特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intel Technologies Ltd
Original Assignee
Intel Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intel Technologies Ltd filed Critical Intel Technologies Ltd
Publication of CN114729358A publication Critical patent/CN114729358A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CN202080070230.9A 2019-08-12 2020-03-06 涉及miRNA-193a的新疗法 Pending CN114729358A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19191222 2019-08-12
EP19191222.9 2019-08-12
EP20160235.6 2020-02-28
EP20160235 2020-02-28
PCT/EP2020/055965 WO2021028081A1 (en) 2019-08-12 2020-03-06 New treatments involving mirna-193a

Publications (1)

Publication Number Publication Date
CN114729358A true CN114729358A (zh) 2022-07-08

Family

ID=69701219

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080070230.9A Pending CN114729358A (zh) 2019-08-12 2020-03-06 涉及miRNA-193a的新疗法

Country Status (7)

Country Link
US (1) US20220275368A1 (https=)
EP (1) EP4013869A1 (https=)
JP (1) JP2022543555A (https=)
CN (1) CN114729358A (https=)
AU (1) AU2020327537A1 (https=)
CA (1) CA3148713A1 (https=)
WO (1) WO2021028081A1 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116850289A (zh) * 2022-07-29 2023-10-10 东北大学 Plk4靶向药物在治疗对铂类药物耐药型肿瘤中的应用
CN117144008A (zh) * 2023-08-31 2023-12-01 武汉科技大学 三阴性乳腺癌生物标志物及其应用
CN118671343A (zh) * 2024-06-25 2024-09-20 南昌大学第一附属医院 一种头颈鳞状细胞癌分子标记物及其应用
CN118987030A (zh) * 2024-07-16 2024-11-22 广东医科大学附属医院 干预嗜碱性粒细胞exosc3在制备预防或治疗狼疮性肾炎药物中的应用
CN119015428A (zh) * 2024-10-29 2024-11-26 中国人民解放军总医院第三医学中心 一种敲低tmem91诱导肾癌细胞死亡和肿瘤免疫治疗肾癌的应用
CN120989248A (zh) * 2025-10-23 2025-11-21 山东第二医科大学 一种检测lncRNA标志物表达量的试剂在制备口腔鳞状细胞癌诊断产品或预后判断产品中的应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3976058A4 (en) * 2019-06-03 2023-07-19 Carmel-Haifa University Economic Corporation Ltd. TREATMENT OF HEAD AND NECK CANCER IN HUMAN
AU2020327537A1 (en) * 2019-08-12 2022-03-03 Interna Technologies B.V. New treatments involving miRNA-193a
CN114672558B (zh) * 2021-12-29 2023-08-04 河北医科大学第三医院 肝癌药物仑伐替尼耐药机制的研究方法
CN118678969A (zh) * 2022-02-22 2024-09-20 株式会社食物流变功能研究所 抗癌剂及抗癌剂的筛选方法
US20250333732A1 (en) * 2022-05-23 2025-10-30 Empirico Inc. Treatment of sos2 related diseases and disorders
WO2025111565A1 (en) * 2023-11-22 2025-05-30 Empirico Inc. Treatment of sos2 related diseases and disorders
WO2025155574A1 (en) * 2024-01-16 2025-07-24 University Of Houston System, Board Of Regents Modulation of akap12 signalosome
WO2026013165A1 (en) * 2024-07-10 2026-01-15 Université Libre de Bruxelles Combination of ship2 inhibitor and plk1 inhibitor for use in the treatment of cancer

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120295832A1 (en) * 2011-05-17 2012-11-22 Arrowhead Research Corporation Novel Lipids and Compositions for Intracellular Delivery of Biologically Active Compounds
US20160193252A1 (en) * 2013-08-14 2016-07-07 Reneuron Limited STEM CELL MICROPARTICLES AND miRNA
US20190192691A1 (en) * 2016-04-11 2019-06-27 Obsidian Therapeutics, Inc. Regulated biocircuit systems
CN111936150A (zh) * 2018-02-12 2020-11-13 因特尔纳技术有限公司 抗癌微小rna及其脂质制剂
US20220275368A1 (en) * 2019-08-12 2022-09-01 Interna Technologies B.V. New treatments involving mirna-193a
US20230136088A1 (en) * 2020-02-28 2023-05-04 Interna Technologies B.V. miRNA-193a for Promoting Immunogenic Cell Death

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000000388A2 (en) 1998-05-15 2000-01-06 Tcs Engineering Services, Inc. Enhanced aircraft cockpit configuration
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
TWI476206B (zh) 2003-07-18 2015-03-11 Amgen Inc 對肝細胞生長因子具專一性之結合劑
FR2872704B1 (fr) 2004-07-12 2007-11-02 Laurent Schwartz Pluritherapie contre le cancer
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
AU2007254853B2 (en) 2006-06-02 2011-11-17 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding proteins
US7649083B2 (en) 2006-06-02 2010-01-19 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding antibody
WO2008010558A1 (en) 2006-07-20 2008-01-24 Panasonic Corporation Ultrasonic probe
WO2009091982A1 (en) 2008-01-18 2009-07-23 Alnylam Pharmaceuticals, Inc. Mir-122 agonist
TW200948380A (en) 2008-04-11 2009-12-01 Galaxy Biotech Llc Combination of HGF inhibitor and PTEN agonist to treat cancer
EP2591106A1 (en) * 2010-07-06 2013-05-15 InteRNA Technologies B.V. Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
EP3369818B1 (en) 2011-12-22 2021-06-09 InteRNA Technologies B.V. Mirna for treating head and neck cancer
WO2019106605A1 (en) 2017-12-01 2019-06-06 Board Of Regents, The University Of Texas System Combination treatment for cancer

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120295832A1 (en) * 2011-05-17 2012-11-22 Arrowhead Research Corporation Novel Lipids and Compositions for Intracellular Delivery of Biologically Active Compounds
US20160193252A1 (en) * 2013-08-14 2016-07-07 Reneuron Limited STEM CELL MICROPARTICLES AND miRNA
US20190192691A1 (en) * 2016-04-11 2019-06-27 Obsidian Therapeutics, Inc. Regulated biocircuit systems
CN111936150A (zh) * 2018-02-12 2020-11-13 因特尔纳技术有限公司 抗癌微小rna及其脂质制剂
US20220275368A1 (en) * 2019-08-12 2022-09-01 Interna Technologies B.V. New treatments involving mirna-193a
US20230136088A1 (en) * 2020-02-28 2023-05-04 Interna Technologies B.V. miRNA-193a for Promoting Immunogenic Cell Death

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ILARIA GROSS等: "Biological Function of MicroRNA193a-3p in Health and Disease", 《INTERNATIONAL JOURNAL OF GENOMICS》, vol. 2017, pages 7 *
JIN, LJ等: "MicroRNA-193a-5p exerts a tumor suppressor role in glioblastoma via modulating NOVA1", 《J OF CELLULAR BIOCHEMISTRY》, vol. 120, no. 4, pages 6188 - 61977 *
LINGQI LIU等: "Downregulation of miR-193a-3p inhibits cell growth and migration in renal cell carcinoma by targeting PTEN", 《TUMOUR BIOL》, vol. 39, no. 6 *
MARION T J CAN DEN BOSCH等: "Transcriptome-wide analysis reveals insight into tumor suppressor functions of 1B3, a novel synthetic miR-193a-3p mimic", 《MOL THER NUCLEIC ACIDS》, vol. 23, pages 1161 - 1171 *
T YU等: "MicroRNA-193a-3p and -5p suppress the metastasis of human non-sall-cell lung cancer by downregulating the ERBB4/PIK3R3/mTOR/S6K2 signaling pathway", 《ONCOGENE》, vol. 34, no. 4, pages 413 - 423, XP037748101, DOI: 10.1038/onc.2013.574 *
YONGHUI LI等，: "Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway", 《BLOOD》, vol. 121, no. 3, XP055693020, DOI: 10.1182/blood-2012-07-444729 *
YONGHUI LI等: "Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway", 《BLOOD》, vol. 121, no. 3, pages 499 - 509, XP055693020, DOI: 10.1182/blood-2012-07-444729 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116850289A (zh) * 2022-07-29 2023-10-10 东北大学 Plk4靶向药物在治疗对铂类药物耐药型肿瘤中的应用
CN117144008A (zh) * 2023-08-31 2023-12-01 武汉科技大学 三阴性乳腺癌生物标志物及其应用
CN117144008B (zh) * 2023-08-31 2024-03-08 武汉科技大学 三阴性乳腺癌生物标志物及其应用
CN118671343A (zh) * 2024-06-25 2024-09-20 南昌大学第一附属医院 一种头颈鳞状细胞癌分子标记物及其应用
CN118987030A (zh) * 2024-07-16 2024-11-22 广东医科大学附属医院 干预嗜碱性粒细胞exosc3在制备预防或治疗狼疮性肾炎药物中的应用
CN119015428A (zh) * 2024-10-29 2024-11-26 中国人民解放军总医院第三医学中心 一种敲低tmem91诱导肾癌细胞死亡和肿瘤免疫治疗肾癌的应用
CN120989248A (zh) * 2025-10-23 2025-11-21 山东第二医科大学 一种检测lncRNA标志物表达量的试剂在制备口腔鳞状细胞癌诊断产品或预后判断产品中的应用

Also Published As

Publication number Publication date
WO2021028081A1 (en) 2021-02-18
CA3148713A1 (en) 2021-02-18
AU2020327537A1 (en) 2022-03-03
EP4013869A1 (en) 2022-06-22
US20220275368A1 (en) 2022-09-01
JP2022543555A (ja) 2022-10-13

Similar Documents

Publication Publication Date Title
CN114729358A (zh) 涉及miRNA-193a的新疗法
US20190077856A1 (en) Method of treating diseases using kinase modulators
US20230295734A1 (en) Bcor rearrangements and uses thereof
US20240009223A1 (en) 6-thio-2'-deoxyguanosine (6-thio-dg) results in telomerase dependent telomere dysfunction and cell death in various models of therapy-resistant cancer cells
US20250146076A1 (en) Alk gene fusions and uses thereof
US20250201339A1 (en) Use of combined cd274 copy number changes and tmb to predict response to immunotherapies
US20250003009A1 (en) Fragment consensus methods for ultrasensitive detection of aberrant methylation
US20240263240A1 (en) Cd274 mutations for cancer treatment
CN115461461A (zh) 用于促进免疫原性细胞死亡的miRNA-193a
EP4423302A2 (en) Novel kinase fusions detected by liquid biopsy
EP4359570A1 (en) Methods of using somatic hla-i loh to predict response of immune checkpoint inhibitor-treated patients with lung cancer
US20250197934A1 (en) Ret gene fusions and uses thereof
WO2025122504A1 (en) Esr1 mutations, esr1 co-occurring mutations, and uses thereof
WO2025122856A1 (en) Use of fibroblast growth factor receptor 3 mutations and tumor mutational burden to predict response to immunotherapies
Lama-Sherpa Elucidating the role of hedgehog signaling in tumor cell response to Dna damage and microenvironmental stress
WO2026030539A1 (en) Alk mutations and uses thereof
WO2025122500A1 (en) Esr1 gene fusions and uses thereof
CN118679268A (zh) 肿瘤突变负荷作为针对癌症治疗中的免疫检查点抑制剂与化学疗法有效性的预测性生物标志物的用途
Ullrich et al. Freie Vorträge
BR112015030822B1 (pt) Vetor, ácido nucleico isolado, composição, método para preparar uma célula t e molécula de ácido nucleico isolada

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220708

WD01 Invention patent application deemed withdrawn after publication